ArticleJournal of diabetes and metabolic disorders2025
Body composition measurement and diabetes - A new perspective on development of antibodies after SARS-CoV-2 booster vaccination.
Article in Journal of diabetes and metabolic disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: In patients with SARS-CoV-2 infection overweight and diabetes are associated with poor prognosis. Therefore, effectiveness and tolerance of booster vaccination against SARS-CoV-2 has to be ensured. We examined the impact of overweight and diabetes on anti-SARS-CoV-2-titers and the incidence of side effects after booster vaccination. Methods: We performed a cross-sectional study with consecutive recruitment and convenience sampling of 100 participants vaccinated three times against SARS-CoV-2. Anti-SARS-CoV-2-titers, immunological parameters and biochemical markers of glucose metabolism were measured. Prevalence of vaccination side effects was assessed by personal interview. Moreover, metabolic status was assessed by performance of body composition measurement and body impedance analysis. The glycemic and metabolic parameters were correlated with the anti-SARS-CoV-2-titers and the incidence of side effects. The results were compared between patient with and without overweight and diabetes. Results: Levels of anti-SARS-CoV-2-titers did not differ between participants with and without overweight (5756.6 ± 6848.9 vs. 4997.0 ± 5050.3, p.83) or participants with and without diabetes (6681.0 ± 6795.2 vs. 5124.0 ± 5070.4 BAU/ml, Conclusions: Overweight and diabetes are not associated with lower anti-SARS-CoV-2-titers after booster vaccination. Parameters of the body composition and body impedance analysis did not reveal any further association regarding development of anti-SARS-CoV-2-titers. Vaccination side effects are more likely to occur in participants without diabetes. Supplementary Information: The online version contains supplementary material available at 10.1007/s40200-025-01699-1.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.